Your browser doesn't support javascript.
loading
Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma.
Homan, Morgan; Warrier, Govind; Lao, Christopher D; Yentz, Sarah; Kraft, Shawna; Fecher, Leslie A.
Afiliación
  • Homan M; Department of Pharmacy, University of Michigan, Ann Arbor, MI, United States.
  • Warrier G; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.
  • Lao CD; Department of Internal Medicine and Dermatology, University of Michigan, Ann Arbor, MI, United States.
  • Yentz S; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States.
  • Kraft S; Department of Pharmacy, University of Michigan, Ann Arbor, MI, United States.
  • Fecher LA; Department of Internal Medicine and Dermatology, University of Michigan, Ann Arbor, MI, United States.
Front Oncol ; 12: 855794, 2022.
Article en En | MEDLINE | ID: mdl-36212431
Combination dabrafenib (D) and trametinib (T) is an FDA approved adjuvant therapy for patients with resected stage III BRAF-mutant melanoma. We describe treatment-related toxicities with adjuvant D+T in a real-world population through a retrospective case series. The primary endpoint was development of toxicities. Results: Eighteen of the 20 patients (90%) required at least one treatment interruption due to adverse events (AEs), 11 patients (55%) required a dose reduction and 13 (65%) permanently discontinued therapy due to an AE. The nine patients who did not require dose reduction had been initiated on a lower starting dose of dabrafenib. The most common treatment-limiting AEs were recurrent pyrexia and chills (85%) and liver laboratory abnormalities (50%). The median total time on therapy was 148.5 days (range 19-383), 40.7% (range 5.2-100%) of the intended one-year duration. Conclusion: Adjuvant treatment of melanoma with combination D+T is associated with treatment-limiting toxicities in the majority of this patient group. Patients should be carefully monitored throughout therapy.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos